Cargando…
Analysis of the disease burden trend of malignant tumors of the female reproductive system in China from 2006 to 2020
BACKGROUND: Malignant tumors of reproductive system seriously threaten women’s life and health. We analyzed the changes in mortality and disease burden of cervical cancer, uterine cancer and ovarian cancer in China from 2006 to 2020 to provide a basis for formulating scientific prevention and contro...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9730658/ https://www.ncbi.nlm.nih.gov/pubmed/36476597 http://dx.doi.org/10.1186/s12905-022-02104-2 |
_version_ | 1784845726603280384 |
---|---|
author | Han, Xiting Wang, Zhihong Huang, Dongmei Deng, Kehong Wang, Qian Li, Cancan Zhu, Jicun |
author_facet | Han, Xiting Wang, Zhihong Huang, Dongmei Deng, Kehong Wang, Qian Li, Cancan Zhu, Jicun |
author_sort | Han, Xiting |
collection | PubMed |
description | BACKGROUND: Malignant tumors of reproductive system seriously threaten women’s life and health. We analyzed the changes in mortality and disease burden of cervical cancer, uterine cancer and ovarian cancer in China from 2006 to 2020 to provide a basis for formulating scientific prevention and control measures. METHODS: Annual death data for cervical cancer, uterine cancer and ovarian cancer were collected from the Chinese Cause of Death Surveillance. The crude mortality rate (CMR), age-standardized mortality rate (ASMR), annual percentage change (APC), and average APC (AAPC) were applied to analyze the trend of mortality. Loss of life expectancy (LLE) and years of life lost (YLL) were used to assess disease burden. RESULTS: From 2006 to 2020, there was no significant change in the total ASMR and standardized YLL rates of malignant tumors of the reproductive system, leading to an average LLE of 0.18 years. The YLL rate was the highest in the 55–59 age group. The mortality rate and disease burden of the three types of cancer have changed from uterine cancer higher than cervical cancer and ovarian cancer in 2006 to cervical cancer higher than ovarian cancer and uterine cancer in 2020. The ASMR and standardized YLL rate of uterine cancer showed a downward trend, and AAPC was − 5.21% (− 9.31% ~ − 0.91%) and − 6.07% (− 9.45% ~ − 2.58%), respectively. The mortality rates of cervical cancer and ovarian cancer remain high. CONCLUSION: The mortality and disease burden of malignant tumors of the female reproductive system in China are still at a high level. It is necessary to improve screening and prevention strategies as soon as possible, improve the techniques of diagnosis and treatment, and take adequate measures to protect women's life and health. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12905-022-02104-2. |
format | Online Article Text |
id | pubmed-9730658 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-97306582022-12-09 Analysis of the disease burden trend of malignant tumors of the female reproductive system in China from 2006 to 2020 Han, Xiting Wang, Zhihong Huang, Dongmei Deng, Kehong Wang, Qian Li, Cancan Zhu, Jicun BMC Womens Health Research BACKGROUND: Malignant tumors of reproductive system seriously threaten women’s life and health. We analyzed the changes in mortality and disease burden of cervical cancer, uterine cancer and ovarian cancer in China from 2006 to 2020 to provide a basis for formulating scientific prevention and control measures. METHODS: Annual death data for cervical cancer, uterine cancer and ovarian cancer were collected from the Chinese Cause of Death Surveillance. The crude mortality rate (CMR), age-standardized mortality rate (ASMR), annual percentage change (APC), and average APC (AAPC) were applied to analyze the trend of mortality. Loss of life expectancy (LLE) and years of life lost (YLL) were used to assess disease burden. RESULTS: From 2006 to 2020, there was no significant change in the total ASMR and standardized YLL rates of malignant tumors of the reproductive system, leading to an average LLE of 0.18 years. The YLL rate was the highest in the 55–59 age group. The mortality rate and disease burden of the three types of cancer have changed from uterine cancer higher than cervical cancer and ovarian cancer in 2006 to cervical cancer higher than ovarian cancer and uterine cancer in 2020. The ASMR and standardized YLL rate of uterine cancer showed a downward trend, and AAPC was − 5.21% (− 9.31% ~ − 0.91%) and − 6.07% (− 9.45% ~ − 2.58%), respectively. The mortality rates of cervical cancer and ovarian cancer remain high. CONCLUSION: The mortality and disease burden of malignant tumors of the female reproductive system in China are still at a high level. It is necessary to improve screening and prevention strategies as soon as possible, improve the techniques of diagnosis and treatment, and take adequate measures to protect women's life and health. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12905-022-02104-2. BioMed Central 2022-12-07 /pmc/articles/PMC9730658/ /pubmed/36476597 http://dx.doi.org/10.1186/s12905-022-02104-2 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Han, Xiting Wang, Zhihong Huang, Dongmei Deng, Kehong Wang, Qian Li, Cancan Zhu, Jicun Analysis of the disease burden trend of malignant tumors of the female reproductive system in China from 2006 to 2020 |
title | Analysis of the disease burden trend of malignant tumors of the female reproductive system in China from 2006 to 2020 |
title_full | Analysis of the disease burden trend of malignant tumors of the female reproductive system in China from 2006 to 2020 |
title_fullStr | Analysis of the disease burden trend of malignant tumors of the female reproductive system in China from 2006 to 2020 |
title_full_unstemmed | Analysis of the disease burden trend of malignant tumors of the female reproductive system in China from 2006 to 2020 |
title_short | Analysis of the disease burden trend of malignant tumors of the female reproductive system in China from 2006 to 2020 |
title_sort | analysis of the disease burden trend of malignant tumors of the female reproductive system in china from 2006 to 2020 |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9730658/ https://www.ncbi.nlm.nih.gov/pubmed/36476597 http://dx.doi.org/10.1186/s12905-022-02104-2 |
work_keys_str_mv | AT hanxiting analysisofthediseaseburdentrendofmalignanttumorsofthefemalereproductivesysteminchinafrom2006to2020 AT wangzhihong analysisofthediseaseburdentrendofmalignanttumorsofthefemalereproductivesysteminchinafrom2006to2020 AT huangdongmei analysisofthediseaseburdentrendofmalignanttumorsofthefemalereproductivesysteminchinafrom2006to2020 AT dengkehong analysisofthediseaseburdentrendofmalignanttumorsofthefemalereproductivesysteminchinafrom2006to2020 AT wangqian analysisofthediseaseburdentrendofmalignanttumorsofthefemalereproductivesysteminchinafrom2006to2020 AT licancan analysisofthediseaseburdentrendofmalignanttumorsofthefemalereproductivesysteminchinafrom2006to2020 AT zhujicun analysisofthediseaseburdentrendofmalignanttumorsofthefemalereproductivesysteminchinafrom2006to2020 |